Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
featured
Published in Oncology

Expert Opinion / Interview · June 19, 2019

Pembrolizumab as First-Line Therapy for Recurrent/Metastatic Head and Neck Cancer

Sumanta Pal MD
Michael Gibson MD, PhD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Sumanta Pal MD

Further Reading

Related Videos